drugset / Trial / NCT00964990

A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia)

NCT00964990

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the safety and effectiveness of JNJ-42160443 in the treatment of moderate to severe neuropathic pain in patients with a diagnosis of postherpetic neuralgia and post-traumatic neuralgia.

Timeline

Start
2009-09
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Fulranumab Monoclonal antibody 1 mg Subcutaneous
Subject Fulranumab Monoclonal antibody 3 mg Subcutaneous
Subject Fulranumab Monoclonal antibody 10 mg Subcutaneous